Parkinson's disease (PD) is a chronic neurodegenerative disorder. Although we do not yet understand its cause, there is extensive degeneration of nigro-striatal DA neurons. Powerful neurotrophic factors, which could be used for the treatment of Parkinson's disease, have been described recently. The ultimate goal of this proposal is to develop novel high-capacity adenoviral systems for long term, stable, non-cytotoxic, and non-immunogenic delivery of neuroprotective genes to the brain for both experimental transgene expression in adult animals, and for the future treatment of chronic neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease by gene therapy. Currently used adenoviruses are efficient vectors for gene transfer into the brain. However, their use has been limited by high doses of vectors needed, vector-cytotoxicity, short-term transgene expression, and deleterious effects of anti-adenovirus inflammatory and immune responses. These limitations are due to: (i) low efficiency of transcriptional promoter elements currently used, which directly leads to the need to use higher doses of vectors, and (ii) cytotoxicity and immunogenicity of viral proteins expressed from the genomes of first generation adenoviral vectors. We now wish to initiate the next stage in the design of efficient, safe, long-term expressing vectors for neurological gene therapy. First, high-capacity helper-dependent adenoviral vectors that express no adenoviral genes will be constructed. Second, the amount of protein produced per input virus will be increased by using stronger promoters alone, or combined with enhancer elements. Third, the efficacy of the new vectors will be tested, by expressing selected neuroprotective genes and verify that they are effective in a model of neurodegeneration. The reagents and principles established by this work will be of substantial value to those with interests in the basic and clinical neurosciences, and will lead to the development of novel approaches to the treatment of chronic neurodegenerative diseases. This research will facilitate the development of the tools needed to achieve long-lived, safe, non-cytotoxic transgene expression, and, ultimately, for the treatment of patients suffering from chronic neurodegenerative disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
3R01NS042893-04S1
Application #
7186292
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Murphy, Diane
Project Start
2002-09-01
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2006-08-31
Support Year
4
Fiscal Year
2006
Total Cost
$62,394
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Mineharu, Yohei; Castro, Maria G; Lowenstein, Pedro R et al. (2013) Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials. Neurol Med Chir (Tokyo) 53:741-54
Sanderson, Nicholas Stephen Rennie; Puntel, Mariana; Kroeger, Kurt M et al. (2012) Cytotoxic immunological synapses do not restrict the action of interferon-ýý to antigenic target cells. Proc Natl Acad Sci U S A 109:7835-40
Zirger, Jeffrey M; Puntel, Mariana; Bergeron, Josee et al. (2012) Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFN?, perforin, and TNF?, and due to the elimination of transduced cells. Mol Ther 20:808-19
Puntel, Mariana; Barrett, Robert; Sanderson, Nicholas S R et al. (2011) Identification and visualization of CD8+ T cell mediated IFN-? signaling in target cells during an antiviral immune response in the brain. PLoS One 6:e23523
Candolfi, Marianela; Kroeger, Kurt M; Xiong, Weidong et al. (2011) Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem 11:729-38
Puntel, Mariana; Muhammad, A K M G; Candolfi, Marianela et al. (2010) A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. J Virol 84:6007-17
Kroeger, Kurt M; Muhammad, A K M Ghulam; Baker, Gregory J et al. (2010) Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med 10:293-304
Pluhar, G Elizabeth; Grogan, Patrick T; Seiler, Charlie et al. (2010) Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 28:3371-8
Yang, J; Sanderson, N S R; Wawrowsky, K et al. (2010) Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc Natl Acad Sci U S A 107:4716-21
Larocque, Daniel; Sanderson, Nicholas S R; Bergeron, Josee et al. (2010) Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A 107:14443-8

Showing the most recent 10 out of 69 publications